PTCH2

Chr 1

patched 2

Also known as: PTC2, SLC65B2

The protein functions as a transmembrane receptor in the hedgehog signaling pathway and acts as a tumor suppressor. Mutations cause somatic basal cell carcinoma and medulloblastoma through a gain-of-function mechanism. The gene has also been associated with nevoid basal cell carcinoma syndrome and congenital macrostomia susceptibility.

GeneReviewsOMIMResearchSummary from RefSeq, OMIM, UniProt, Mechanism
LOFmechanismLOEUF 0.852 OMIM phenotypes
Clinical SummaryPTCH2
🧬
Gene-Disease Validity (ClinGen)
nevoid basal cell carcinoma syndrome · ADLimited

Limited evidence — not for standalone diagnostic reporting

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
6 unique Pathogenic / Likely Pathogenic· 410 VUS of 700 total submissions
📖
GeneReview available — PTCH2
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.85LOEUF
pLI 0.000
Z-score 2.43
OE 0.64 (0.480.85)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
0.78Z-score
OE missense 0.92 (0.860.98)
638 obs / 696.3 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.64 (0.480.85)
00.351.4
Missense OE0.92 (0.860.98)
00.61.4
Synonymous OE1.00
01.21.6
LoF obs/exp: 33 / 51.9Missense obs/exp: 638 / 696.3Syn Z: 0.04
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
limitedPTCH2-related Gorlin syndromeLOFAD
DN
0.7132th %ile
GOF
0.74top 25%
LOF
0.2680th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

700 submitted variants in ClinVar

Classification Summary

Pathogenic3
Likely Pathogenic3
VUS410
Likely Benign245
Benign23
Conflicting6
3
Pathogenic
3
Likely Pathogenic
410
VUS
245
Likely Benign
23
Benign
6
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
1
2
0
3
Likely Pathogenic
1
0
2
0
3
VUS
44
340
23
3
410
Likely Benign
0
3
91
151
245
Benign
0
0
19
4
23
Conflicting
6
Total45344137158690

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

PTCH2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →